利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

594 条记录 (耗时 0.028 秒)

    DHEA BIOADHESIVE CONTROLLED RELEASE GEL
    52.
    发明申请
    DHEA BIOADHESIVE CONTROLLED RELEASE GEL 有权
    DHEA BIOADHESIVE控制释放凝胶

    公开(公告)号：US20150297510A1

    公开(公告)日：2015-10-22

    申请号：US14688603

    申请日：2015-04-16

    申请人： DHEA LLC

    发明人： MICHAEL S. RIEPL

    IPC分类号： A61K9/00 ,  A61K31/355 ,  A61K31/566

    CPC分类号： A61K31/5685 ,  A61K9/0034 ,  A61K9/06 ,  A61K31/00 ,  A61K31/355 ,  A61K31/566 ,  A61K47/32

    摘要： The DHEA bioadhesive controlled release gel includes DHEA mixed in a polymeric gel for the purpose of treating atrophic vaginitis, vaginal dryness, dyspareunia, itching, burning, irritation, increase in pH and decreased vaginal flora. The gel adheres to vaginal tissue and protects the DHEA from systemic absorption, which prevents leakage, loss of DHEA, and elevated levels of systemic DHEA. The gel is configured to slowly erode over time so as to deliver a predetermined dose of DHEA to vaginal tissue and thereby promote local intracellular conversion to estrogens, androgens and progesterone so that normal levels of fluid in the vagina is produced. The gel also acts as a moisturizer. An adjustable applicator may also be provided to insure proper placement and dose of the DHEA.

    摘要翻译： DHEA生物粘附控制释放凝胶包括混合在聚合物凝胶中的DHEA，用于治疗萎缩性阴道炎，阴道干燥，性交疼痛，瘙痒，燃烧，刺激，pH增加和阴道菌落减少。 凝胶粘附于阴道组织并保护DHEA免受全身吸收，从而防止DHEA的渗漏，DHEA的损失以及全身DHEA水平升高。 凝胶被配置为随时间缓慢侵蚀，以将预定剂量的DHEA递送到阴道组织，从而促进局部细胞内转化为雌激素，雄激素和孕酮，从而产生阴道中的正常水平的液体。 凝胶也起保湿作用。 还可以提供可调整的施用器以确保DHEA的适当放置和剂量。

    VERY LOW-DOSED SOLID ORAL DOSAGE FORMS FOR HRT
    55.
    发明申请
    VERY LOW-DOSED SOLID ORAL DOSAGE FORMS FOR HRT 审中-公开
    用于HRT的极低剂量固体口服剂型

    公开(公告)号：US20150094287A1

    公开(公告)日：2015-04-02

    申请号：US14564076

    申请日：2014-12-08

    申请人： Bayer Intellectual Property GmbH

    发明人： Stephan MLETZKO ,  Rolf SCHÜRMANN ,  Kerstin GUDE

    IPC分类号： A61K31/585 ,  A61K31/566

    CPC分类号： A61K31/585 ,  A61K31/565 ,  A61K31/566 ,  A61K31/57

    摘要： The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.

    摘要翻译： 本发明涉及用于激素替代疗法（HRT）的非常低剂量的剂型。 更具体地，本发明涉及包含约0.5mg雌二醇和约0.25mg屈螺酮和至少一种药学上可接受的赋形剂的固体口服剂型。 尽管E2和DRSP剂量非常低，但令人惊讶地发现，中度至重度热潮红的妇女中，很大一部分实际上对这种治疗有反应。 因此，本发明的剂型可用作维持HRT，或者可以在HRT起始时已经使用本发明的剂型。

    DERMAL DELIVERY DEVICE WITH IN SITU SEAL
    57.
    发明申请
    DERMAL DELIVERY DEVICE WITH IN SITU SEAL 审中-公开
    带密封件的DERMAL DELIVERY设备

    公开(公告)号：US20140350493A1

    公开(公告)日：2014-11-27

    申请号：US14264427

    申请日：2014-04-29

    申请人： Agile Therapeutics, Inc.

    发明人： Agis KYDONIEUS ,  Robert G. CONWAY ,  Thomas M. ROSSI

    IPC分类号： A61K9/70 ,  A61K47/14 ,  A61K31/567 ,  A61K31/566 ,  A61K31/568 ,  A61K47/20 ,  A61K31/573

    CPC分类号： A61K9/7061 ,  A61F2013/00646 ,  A61K9/7084 ,  A61K31/566 ,  A61K31/567 ,  A61K31/568 ,  A61K31/573 ,  A61K47/14 ,  A61K47/20

    摘要： This invention relates to a transdermal drug delivery device that comprises an active ingredient (AI) layer, having a skin contacting surface and a non-skin contacting surface and comprising a volatile component, a release liner impermeable to the volatile component adjacent the skin contacting surface of the Al layer having a perimeter that extends beyond the perimeter of the Al layer in all directions, and an overlay comprising a pressure sensitive adhesive (PSA) that does not absorb the volatile component adjacent the non-skin contacting surface of the Al layer having a perimeter of which extends beyond the perimeter of the Al layer in all directions, wherein the release liner and the PSA of the overlay are in contact with and adhered to each other around the perimeter of the Al layer to form a seal that reduces or prevents volatile component loss.

    摘要翻译： 本发明涉及一种透皮药物递送装置，其包含活性成分（AI）层，其具有皮肤接触表面和非皮肤接触表面，并且包含挥发性成分，不透过皮肤接触表面的挥发性组分的剥离衬垫 的Al层具有在所有方向上延伸超出Al层的周边的周边，以及覆盖层，其包含不吸收与Al层的非皮肤接触表面相邻的挥发性组分的压敏粘合剂（PSA），所述粘合剂 其周边在所有方向上延伸超出Al层的周边，其中覆盖层的剥离衬垫和PSA与Al层的周边彼此接触并彼此粘附以形成密封，以减少或防止 挥发性成分损失。

    METHOD FOR INDUCING TWIN CALVING
    58.
    发明申请
    METHOD FOR INDUCING TWIN CALVING 有权
    诱导双卡方法

    公开(公告)号：US20140349934A1

    公开(公告)日：2014-11-27

    申请号：US14285541

    申请日：2014-05-22

    申请人： China Agricultural University

    发明人： Jianhui TIAN ,  Weibin ZENG ,  Lei AN ,  Shumin WANG ,  Zhonghong WU

    IPC分类号： A61K38/24 ,  A61K31/566 ,  A61K31/557 ,  A61K31/57

    CPC分类号： A61K38/24 ,  A61K31/557 ,  A61K31/566 ,  A61K31/57

    摘要： The present invention provides a method for inducing twin calving. The method according to the present invention comprises firstly treatment to inducing atresia of the antral follicles on ovary so as to initiate the development of new follicular wave, inducing the development of codominant follicles and further achieving double ovulations by exactly controlling the dosage and time points of hormone injections, and performing artificial insemination to induce the cow to deliver twin calves. The method according to the present invention has relative independent on the technical skills, and a person skilled in the art or a common worker can practice it according to specified operation methods; and during practical application, it does not require special equipment, thus saving cost, as well as improving the social benefit and economic benefit of cow breeding.

    摘要翻译： 本发明提供一种诱导双犊的方法。 根据本发明的方法首先包括在卵巢上诱导窦卵泡闭锁，以引发新卵泡波的发育，诱导共显性卵泡的发育，并通过精确控制剂量和时间点进一步实现双重排卵 激素注射，并进行人工授精以诱导母牛交付双犊牛。 根据本发明的方法相对独立于技术技能，本领域技术人员或普通工人可以根据指定的操作方法来实施; 在实际应用中，不需要特殊设备，节省成本，提高养殖的社会效益和经济效益。